Trich Challenge

As of 2021, the ____________ regimen is no longer recommended by the CDC and ACOG for the treatment of trichomoniasis in women.2,3

CDC and ACOG no longer recommend single dose metronidazole for the treatment of trichomoniasis in women2,3


Guidelines changed because the 2 g single-dose regimen demonstrated comparatively inferior efficacy in two separate studies—one in HIV-infected and one in HIV-uninfected women4,5:

Research has shown that what percentage of patients do not adhere to a full course of metronidazole treatment (500mg BID x 7d)6?

To get the full benefit of a drug's studied efficacy, it is important for patients to fully adhere to treatment as prescribed.7


SOLOSEC 2 g ONCE


1 dose
Metronidazole 500 mg
BID x 7 days*


14 doses
*CDC recommended oral regimen for both BV and trichomoniasis
SOLOSEC effectively treats both BV and trichomoniasis with just one oral dose1.

Which intravaginal treatments are recommended for the treatment of trichomoniasis?

SOLOSEC is the only antibiotic therapy that delivers a complete course of treatment for BV and trichomoniasis in just one oral dose1

solosec and current treatments for bacterial vaginosis comparison chart
side scroll icon
current treatments for bacterial vaginosis comparison chart
current treatments for bacterial vaginosis comparison chart
* Combination oral contraceptive ethinyl estradiol plus norethindrone
The comparative efficacy of SOLOSEC with the listed treatments has not been adequately studied. This is not a complete list of attributes for each product that may be important to a clinical decision. For the most updated information, consult the PI for each product.

Approximately what percentage of trich patients were also PCR-positive for the bacteria that cause BV?

Co-existence of trichomoniasis and BV-related pathogens is common.13

Bacterial vaginosis (BV) provides a high pH, creating a favorable environment for T. vaginalis.
14
Vaginal pH

SOLOSEC provides a complete course of therapy with one oral dose.1


What's the half-life of SOLOSEC?

Comparative Half-Lives of 5-Nitroimidazole Compounds15,16


The long half-life of secnidazole supports a 1-day, single dose regimen of SOLOSEC.15
The long half-life of secnidazole supports a 1-day, single dose regimen of SOLOSEC.15



SOLOSEC offers an effective solution to assure adherence in patients and partners without the need for multiple days of pills.1



Select the perinatal complications that have been associated with trichomoniasis.2,17,18

Trichomoniasis has been associated with a range of serious perinatal complications.2
SOLOSEC has no pregnancy restrictions.1*
* Available data on pregnancy are limited to animal studies.
Metronidazole and tinidazole are contraindicated in the first trimester of pregnancy.5,6
Metronidazole and tinidazole are contraindicated in the first trimester of pregnancy.5,6

Select the health risk below that is NOT associated with trichomoniasis.2,19-22

Untreated or inadequately treated trichomoniasis is associated with serious health risks and reproductive morbidity:
Pelvic inflammatory disease (PID)20
Acquisition of STIs21
((gonorrhea, chlamydia, HPV and HSV)
Acquisition or transmission of HIV21
Cervical cancer19
Pregnancy
complications 17,18
(pre-term birth, low birth weight, premature rupture of membranes, chorioamnionitis)
Pelvic inflammatory disease (PID)20
Acquisition of STIs21
((gonorrhea, chlamydia, HPV and HSV)
Acquisition or transmission of HIV21
Cervical cancer19
Pregnancy complications 17,18
(pre-term birth, low birth weight, premature rupture of membranes, chorioamnionitis)

CDC recommends screening for trichomoniasis in all women seeking care for vaginal discharge.2

Recurrence of trichomoniasis is most likely due to:

Trichomoniasis is highly recurrent, likely due to reinfection by infected partners.2



Trichomoniasis Recurrence23


Left untreated, trichomoniasis can persist for months—or years.2

Partners of trichomoniasis patients should be treated with the same dose, at the same time.1,2


With SOLOSEC, patients and partners can complete treatment for trichomoniasis with a single, effective 2 g oral dose



References:
1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(RR-04):1-192. 3. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists, Number 215. Obstet Gynecol 2020:135(1):e1-e17. 4. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55:565–71. 5. Kissinger P, Muzny C, Mena L, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomised controlled. Lancet Infect Dis 2018;18(11):1251-1259. 6. Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis 2004;31(8):488-491.23. 7. Kardas P, Bishai WR. Compliance in anti-infective medicine. Adv Stud in Med. 2006:6(July);652-658. 8. Flagyl [prescribing information]. New York, NY: Pfizer; 2021. 9. Tinidazole Tablets [prescribing information]. Buffalo Grove, IL: G.D. PACK Pharmaceuticals, LLC; 2018. 10. Clindesse [prescribing information]. Allegan, MI: Pharmacia & Upjohn Company, LLC; 2014. 11. Metrogel [prescribing information]. Sellersville, PA. Teva Pharmaceuticals, USA; 2005. 12. Nuvessa [prescribing information. Irvine, CA: Allergan Pharmaceuticals International, Ltd.; 2018. 13. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax S. Mixed Vaginitis—More than Coinfection and with Therapeutic Implications. Curr Infect Dis Rep 2013;15:104-108. 14. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-4617. 15. Nyirjesy P, Schwebke JR. Secnidazole: Next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol 2018;13:507-524. 16. Gillis JC, Wiseman LR. Secnidazole. A Review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996;51(4):621-638. 17. Van Gerwen OT, Craig-Kuhn MC, Jones AT et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. BJOG 2021. 18. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997;24:353-360 and 563-568. 19. Yang S, Zhao W, Wang H, et al. Trichomonas vaginalis infection-associated risk of cervical cancer: A meta-analysis. Euro J Obstet Gynecol 2018;228:166-173. 20. Wiringa AE, Ness RB, Darville T et al. Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. Sex Transm Infect 2020;96:436-438. 21. Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis 2009;36(12):738–44. 22. Persson E, Bergstrom M, Larsson PG et al. Infections after hysterectomy. A prospective nation-wide Swedish study. Acta Obstet Gynecol Scand 1996;75(8):757-761. 23. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006;145:564–72.